Genomic deletions involving chromosome 4 have recently been implicated in several human cancers. To identify and characterize genetic events associated with the development of head and neck squamous cell carinoma (HNSCC), a ®ne mapping of allelic losses associated with chromosome 4 was performed on DNA isolated from 27 matched primary tumor specimens and normal tissues. Loss of heterozygosity (LOH) of at least one chromosome 4 polymorphic allele was seen in the majority of tumors (92%). Allelic deletions were con®ned to short arm loci in four tumors and to the long arm loci in 12 tumors, suggesting the presence of two regions of common deletion. One region of frequent deletion was centered at D4S405 on 4p and included the loci D4S1546 to D4S428 in *41% of the tumors. The common region of deletion on 4q was more complex and extended from D4S1571 to D4S1573. Frequent genetic alterations were observed within this region (4q25) and one marker, D4S407, exhibited a high frequency of LOH (475%). These results indicate that alterations of chromosome 4 regions are associated with HNSCC tumorigenesis and further localizes the regions that may harbor tumor suppressor genes.
Introduction
Approximately 50 000 North Americans will be diagnosed with head and neck squamous cell carcinoma (HNSCC) this year and over 14 000 will succumb to the disease (DeVesa et al., 1995) . Etiological factors for HNSCC include tobacco and alcohol use, along with occupational exposure to carcinogens, implying that damage to DNA plays a major role in the oncogenesis of this cancer (Vokes et al., 1993) . This is further supported by studies demonstrating mutagen-induced chromosomal fragility as an independent risk factor (Spitz et al., 1993) . However, the molecular events in HNSCC are still poorly understood (Hong et al., 1995; Sidransky, 1995) . By better de®ning the molecular genetic basis of tumor initiation and progression in HNSCC, new insights into the biological behavior, diagnosis, and possible new therapeutic approaches may be forthcoming.
Cytogenetic studies have identi®ed recurring, but widely varied alterations of chromosomes 1, 3, 4, 5, 7, 8, 9, 11, 14, 15 and 17 (Jin et al., 1993; Sreekantaiah et al., 1994) . Although several molecular studies have shown that mutation of p53 and ampli®cation of epidermal growth factor receptor are relatively common events. However, the exact genes that are targeted in the majority of the observed chromosomal alterations are unknown (Brachman et al., 1992; Grandis et al., 1993; Shin et al., 1994) . Recently, several groups have performed allelotyping studies on HNSCC specimens to further de®ne regions of consistent loss. Frequent loss of heterozygosity (LOH) was observed on chromosome arms 3p, 5q, 9p, 11q and 17p, with less frequent losses on 4, 6p, 8, 14q, 18 and 19q (Nawroz et al., 1994; Ah-See et al., 1994; El-Naggar et al., 1995) . The combination of these observations suggest that multiple molecular alterations are responsible for the oncogenesis of HNSCC.
Our interest in chromosome 4 results from an observation that the microcell-mediated chromosomal transfer of chromosome 4 in human gliomas resulted in the suppression of the tumorigenicity of glioma cells (Pershouse et al., submitted) . The putative tumor suppressor locus associated with this observed phenotypic suppression was further localized to a region (47 cM) near the epidermal growth factor gene on 4q. This study was undertaken to further examine the occurrence and location of regions of common deletion involving chromosome 4, particularly associated with the long arm in HNSCC.
Results
Tumor specimens from 27 patients with various grades of HNSCC were screened for LOH with a panel of 27 microsatellite markers speci®c for chromosome 4 loci. Typical autoradiographs of the markers D4S408 and D4S1546 illustrating LOH and retention of alleles are shown in Figure 1 . The overall frequency of deletion at each locus and their ordering is depicted in Figure 2 . Two tumors showed no loss of chromosome 4 loci (tumors #36 and 48). Alternatively, two other tumors (#4 and 8) displayed extensive losses, suggesting the deletion of all or most of chromosome 4 in these neoplasms. Allelic alterations (alleles not present in the matched normal specimens) were observed in six of 27 specimens (22%), with three tumors (#41, 44, and 46) showing alterations at several markers.
The majority of tumors (22 of 27, 81%) had deletions and/or alterations associated with the long arm of chromosome 4. Twelve tumor specimens revealed deletions con®ned only to 4q (Table 1; Figure  3 , groups A and B). All of the tumors with deletions on 4q involved at least an area at 4q25 from the markers D4S1571 to D4S1573 which represents a region of about 7 cM (Gyapay et al., 1994) . Two patterns of allelic losses within this region were de®ned. One series of tumor specimens exhibited a continuous region of possible deletions within this critical area at 4q25 (boxed markers Figure 3a) . A common region of loss was centered at D4S1616 and involved the adjacent markers D4S1553 to D4S407 (*1.5 mb). Breakpoints involving LOH and retention of alleles in tumors #6 and 41 would indicate a consistent region of deletion surrounding D4S1616. A similar pattern of continuous deletions was de®ned for tumors with allelic losses involving both the long and short arm of the chromosome (Figure 3 , group C1). However, for this series of tumors, only the region surrounding D4S407 was consistently involved. The combination of these two series of tumors would suggest a minimal region of involvement between D4S1616 and D4S407, as illustrated by breakpoints in tumors (#6 and 43). Two tumors (#11 and 53) revealed continuous deletion of the area D4S1616-D4S407, but had an additional area of deletion telomeric to 4q25.
A second more complex pattern of allelic losses for 4q25 was also observed involving the same region. However, this series of tumors displayed two areas of deletions accompanied by two markers within this region, EGF and D4S193, that showed frequent retention. A similar pattern was seen for tumors with and without allelic losses on the p arm ( Figure 3 , groups C2 and B, respectively). The most centromeric region of consistent deletion was centered at D4S1553, while the more telomeric region was centered at D4S1616 and extended from D4S1651 to D4S1611.
Four tumors (#5, #43, #44, and #45) displayed losses associated only with the short arm of the chromosome (Table 1) . Overall, LOH on 4p was shown in 11 of the 27 (41%) of the tumors examined. Of these, four (14%) had potentially lost the entire arm ( Figure 4) . A minimum area of deletion involved the markers D4S405 and D4S428. Three tumors (#44, 45, and 52) have single parm, deletions at D4S405. One tumor (#53) displayed a deletion towards the centromeric side suggesting a potential critical region between D4S405 and D4S428, although this tumor displayed multiple regions of deletion, indicating a complex cytogenetic rearrangement. An additional tumor (#43) revealed a deletion only at the short arm telomeric marker D4S412.
Comparison of the allelic deletions on either the short or long arm of chromosome 4 to tumor grade, location or histological dierentiation suggested no signi®cant correlations. Furthermore, we failed to observe any relationship between the number of deletions per specimen and the histological differentiation. Since the allelic deletions were found in all grades and stages of tumors, this would suggest that deletion involving chromosome 4 may represent an early event in HNSCC oncogenesis.
Discussion
The functional loss of tumor suppressor genes is intimately associated with the initiation and/or progression of human cancers (Weinberg, 1991) . LOH in HNSCC has been described for a number of chromosomes (Nawroz et al., 1994; Ah-See et al., 1994) , however, ®ne mapping of common deletions has mainly focused on chromosomes 3p, 11p, 13q and 17p exhibiting frequent deletions (450%). The involvement of LOH on chromosome 4 alleles has only recently been observed in HNSCC and several other carcinomas including hepatocellular, bladder, ovarian and cervical (Buetow et al., 1989; Sato et al., 1991; Mitra et al., 1994; Fujimoto et al., 1994; Polascik et al., 1995) . For HNSCC the allelic deletions associated with chromosome 4 were considered relatively infrequent compared to other chromosomal alterations and unexpected' as previous reports failed to implicate this chromosome (Narwoz et al., 1994) . Although only one marker per arm was used in the latter study. The results from our study illustrate a higher frequency of loss associated with chromosome 4 with 92% of the specimens showing allelic deletion involving chromosome 4. Furthermore, two regions of common deletion were observed: (1) a large area involving the centromeric region of the short arm centered at D4S405 and (2) a smaller region showing complex alterations that involved at least 4q25. Alterations to each region appear to be independent as individual tumors displayed only p-or q-arm deletions.
Functional evidence for tumor suppressor genes on chromosome 4 has been provided by several studies. Phenotypic tumor suppression has been observed with introduction of chromosome 4 into teratocarcinoma cells (McGowan-Jordan et al., 1994) . The presence of a senescence gene on chromosome 4 was also shown by chromosomal transfer (Ning et al., 1991) . Recently, the transfer of an intact copy of chromosome 4 or a fragment of the chromosome retaining the region surrounding EGF gene in human glioma cells was demonstrated to suppress the tumorigenic phenotype of the parental cells (Pershouse et al., submitted) . This latter study focused our eorts at de®ning deletions associated with 4q in additional human cancers.
The highest frequency of deletion in our study was found at 4q25 surrounding the EGF locus. This locus was previously implicated in an allelic deletion study of hepatocellular carcinomas (Buetow et al., 1989) . Also, an investigation of cervical carcinomas showed the region 4q23-25 displayed frequent LOH (Mitra et al., 1994) . However, in our localization analysis of LOH directed at 4q, two patterns of deletion were observed in the region 4q23-25. The independent deletion patterns do not appear to be due to artifactual factors as the incorrect ordering of the allelic markers was excluded from YAC contig data and identical results were obtained from duplicate experiments. This raises several possible alternative explanations. First, the observed retention of heterozygosity within the region EGF to D4S193 could be due to ampli®cation of alleles in contaminating normal cells in the sections, thus masking an area of homozygous deletion . This possibility is well illustrated by tumor #46 where the vast majority of allelic markers of chromosome 4 exhibit LOH except for the area EGF to D4S407. Unfortunately, sucient DNA from the microdissected specimens was not available to test this possibility by Southern blotting. An alternative possibility is that the region (EGF ± D4S193) may contain a critical gene(s) that would have a negative impact on cell viability, even if only one copy of the gene is lost, thus the area is preferentially retained. The retention of these loci in our suppressed somatic cell hybrids containing fragments of chromosome 4 would favor this possibility (Pershouse et al., submitted) . A third possibility is that the region D4S423 to D4S400 could represent a third area of deletion in HNSCC in a subset of the tumors. Support 2  2  2  2  2  3  2  2  3  2  1  2  3  2  2  2  1  2  3  1  2  2  3  2  3  3  3   IV  III  IV  II  IV  IV  IV  III  IV  IV  IV  IV  IV  IV  III  II  I  IV  III  III  IV  II  IV  III  I  III for this possibility is that the common regions of deletion de®ned by groups A and C1 and B and C2 do not overlap. A fourth possibility is that the region is genetically unstable and retention or deletion of the loci surrounding EGF and D4S193 may both occur, but the resulting genetic recombinations within the region may eect a distal tumor suppressor locus. This is supported by the observation that IF and EGF genes are genetically 3 cM apart, yet physically map to the same YAC 416e1 at 330 kb (Fan et al., 1994) , suggesting frequent recombination within the region. Distinguishing among these various possibilities will require further extensive analyses.
The observed frequency of LOH on the p-arm in this study is similar to that previously reported for HNSCC with approximately 40% of the specimens exhibiting losses (Nawroz et al., 1994) . A recent report in bladder carcinomas has identi®ed two critical regions of LOH on chromosome 4 ; one region maps to the p-arm between markers D4S1608 and D4S404. This area is smaller and more telomeric than the region of most frequent deletion observed in our specimens, which is centered at D4S405. However, additional ®ne mapping of these regions would be required to determine if they overlap. The other region of common deletion in bladder carcinoma mapped near the telomere on the long arm of chromosome 4 between markers D4S408 and D4S426. In our cohort, infrequent deletions were observed in this region in our HNSCC specimens, although three tumors (#11, #46 and #53) may harbor independent chromosomal aberrations in this region. Table 1 Figure 4 Summary of allelic loss at 8 loci on 4p in 27 HNSCC tumors. Tumors correspond to those in Table 1 . Boxed areas represent regions of potential loss, losses in conjunction with adjacent non-informative markers The combination of allelic deletions and chromosomal transfer studies strongly suggest the presence of a tumor suppressor gene with 4q24-26. This region was involved in 480% of the tumors examined, suggesting that a putative chromosome 4q tumor suppressor gene may play an important role in the evolution of HNSCC. This is underscored by the lack of associations between allelic loss and clinopathologic characteristics in our cases. Eorts are currently underway to further molecularly de®ne the alterations aecting this region in order to search for candidate tumor suppressor genes.
Materials and methods

Tissue samples
Twenty-seven HNSCC tumors were prospectively accessioned in the Frozen Section Unit of the Department of Pathology, MD Anderson Cancer Center from 1991 to 1993. Peripheral blood lymphocytes from each patient were collected after Ficoll-Hypaque centrifugation. Tumor samples were carefully trimmed to remove normal ®brous material and veri®ed by frozen section and cytospin preparation to contain 515% non-tumorous elements. Tissue samples from each specimen were immediately snap frozen and kept at 7808C until used.
Microsatellite polymorphism analysis
For preparation of high molecular weight DNA, frozen tissues were ground in a lysing buer containing 0.2 M Tris-Cl, 1% SDS, 0.25 M NaCl, 25 mM EDTA (pH 8.5) followed by addition of Proteinase-K to a ®nal concentration of 200 mg/ml. After 24 h at 508C, the DNA was puri®ed by extraction with phenol/chloroform and precipitated with ethanol. DNA was also extracted from peripheral blood lymphocytes from the appropriate patients (El-Naggar et al., 1995) .
Microsatellite repeat DNA polymorphisms are examined by PCR with slight modi®cations to previous methods (Weber and May, 1989; Pershouse et al., 1993) . PCR primers were obtained from Research Genetics (Huntsville, AL) or were synthesized from published sequences . PCR (25 ml) reactions were mixed as follows, 60 ng of DNA template, 12 pMoles of each primer, 6 ml of premixed PCR mix (0.833 mM dATP, 0.833 mM dCTP, 0.833 mM dTTP, 0.833 mM dGTP, 4.17 mM Tris-HCl, 41.67 mM NaCl, 2.08 mM MgCl 2 and 0.417 mM 2-mercaptoethanol), 0.16 ml [a 32 P]dCTP, 0.625 U Taq polymerase. The PCR products were generated during standard PCR reactions consisting of an initial 5 min, 948C denaturation step followed by 25 cycles of 948C, 45 s; 558C, 45 s; 728C, 45 s, followed by ®nal 3 min at 728C. Resolution of the polymorphic bands was accomplished by denaturing polyacrylamide gel electrophoresis (6% acrylamide, 8% urea, Sequegel; run at 80 watts for 2 ± 3 h) utilizing a Bio Rad 38650 cm sequencing apparatus. The gels were vacuum dried and exposed to X-ray ®lm with intensifying screen at 7708C for 4 ± 48 h. Physical mapping data was based upon the Genethon map of chromosome 4 (Gyapay et al., 1994) .
